Drug Safety

, Volume 32, Issue 6, pp 499–507 | Cite as

Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England

Interim Results from a Prescription-Event Monitoring Study
  • Rachna Kasliwal
  • Lynda V. Wilton
  • Saad A. W. Shakir
Short Communication

Abstract

Background: Varenicline tartrate (Champix®), a new smoking cessation medicine, was launched in the UK in December 2006. Varenicline is a highly selective partial agonist of the α4β2 nicotinic acetylcholine receptor (α4β2 receptor). The partial agonistic binding leads to alleviation of symptoms of craving and withdrawal, and simultaneously prevents nicotine from binding to the α4β2 receptor thereby causing reduction in the rewarding and reinforcing effects of smoking. Regulatory concerns have arisen about psychiatric events associated with varenicline, including depression, suicidal ideation and changes in behaviour/emotion.

Aim: To present the interim results of an ongoing study by the Drug Safety Research Unit (DSRU) monitoring the safety of varenicline.

Methods: The observational cohort study is being conducted to study the postmarketing safety of varenicline, using modified prescription-event monitoring (PEM) methodology. Patients are identified from dispensed prescriptions issued by general practitioners (GPs) from December 2006. Demographic, clinical event (during the course and 1 month after stopping varenicline, reasons for discontinuing and suspected adverse drug reactions [ADRs] to varenicline) and drug utilization data are collected from detailed study-specific questionnaires posted to GPs at least 4 months after the date of first prescription for each patient. Event incidence densities (IDs; number of first reports of an event/1000 patient-months of exposure) are calculated.

Results: The interim cohort comprises 2682 patients: median age 47 years (interquartile range [IQR] 38–56), 60.7% females (n = 1627). Nausea/vomiting was the most frequent clinical reason for stopping varenicline (n = 91; 35.3% of clinical reasons) and the most frequently reported suspected ADR to varenicline (n = 60, 50.9% of patients for whom an ADR was reported). The most frequently reported psychiatric events (causality not implied) during treatment included (n; % of cohort): sleep disorder (43; 1.6%), anxiety (33; 1.2%), depression (29; 1.1%), abnormal dreams (26; 1.0%) and mood change (17; 0.6%). Two cases of attempted suicide were reported during treatment with varenicline (one patient took an overdose of a benzodiazepine with alcohol, the other slashed their wrist). Both these patients had previous history of psychiatric illness and precipitating factors for the event.

Conclusion: This study reflects ‘real life’ use of varenicline. Nausea/vomiting 3-the event most frequently reported as an ADR and as reason for stopping treatment —is listed in the UK Summary of Product Characteristics (SPC). The most frequently reported psychiatric events are listed in the UK SPC. All patients with suicidal events either had a past medical history of psychiatric illness prior to starting varenicline and/or a precipitating factor for the event. Clinicians should closely monitor patients with pre-existing psychiatric illness who are taking varenicline. Further evaluation of events of interest including psychiatric events is ongoing. Results presented are expected to change as the cohort size increases. Results of this study should be taken into account together with other clinical and pharmacoepidemio-logical studies.

References

  1. 1.
    European Medicines Agency. EPAR for Champix: scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/champix/H-699-en6.pdf 2006 [Accessed 2008 May]
  2. 2.
    Summary of product characteristics for Champix (varenicline tartrate). Kent: Pfizer Ltd, 2006 Dec [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2006 Dec 11]
  3. 3.
    Medicines and Healthcare products Regulatory Agency. Varenicline: possible effects on driving; psychiatric illness. London: Drug Safety Update, 2007. Report no. 1 (5)Google Scholar
  4. 4.
    US Food and Drug Administration Centre for Drug Evaluation and Research. Early communication about an ongoing safety review: varenicline, November 20, 2007 [online]. Available from URL: http://www.fda.gov/medwatch/safety/2007/safety07.htm#Chantix [Accessed 2008 Jul 14]
  5. 5.
    Summary of product characteristics for Champix (varenicline tartrate). Kent: Pfizer Ltd, 2008 Mar [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2008 Apr 14]
  6. 6.
    Shakir S. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 203–16Google Scholar
  7. 7.
    British Medical Association Board of Science, British Medical Association Science & Education. Reporting adverse drug reactions: a guide for healthcare professionals [online]. Available from URL: http://www.bma.org.uk/ap.nsf/Content/AdverseDrugReactions [Accessed 2006 May 15]
  8. 8.
    Guidelines on the practice of ethical committees in medical research involving human subjects. London: Royal College of Physicians of London, 1996Google Scholar
  9. 9.
    General Medical Council. Frequently asked questions supplement to: Confidentiality —protecting and providing information [pamphlet]. London: General Medical Council (gmc-uk.org), 2004: 9Google Scholar
  10. 10.
    US Food and Drug Administration Centre for Drug Evaluation and Research. Public health advisory: important information on Chantix (varenicline), February 1, 2008 [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/varenicline.htm [Accessed 2008 Jul]
  11. 11.
    Medicines and Healthcare products Regulatory Agency. Varenicline: drug analysis, June 2008 [online]. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Medicines/Reportingsuspectedadversedrugreactions/Druganalysisprints/index.htm?indexChar=V [Accessed 2008 Jul 14]
  12. 12.
    Health Canada. Canadian adverse reaction newsletter: varenicline (Champix) and serious psychiatric reactions, April 2008 [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v18n2-eng.php#1 [Accessed 2008 Jul]
  13. 13.
    Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline [letter]. Am J Psychiatry 2008 Jun; 165(6): 774PubMedCrossRefGoogle Scholar
  14. 14.
    Freedman R. Exacerbation of schizophrenia by varenicline [letter]. Am J Psychiatry 2007 Aug; 164(8): 1269PubMedCrossRefGoogle Scholar
  15. 15.
    Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007 Aug; 164(8): 1269–70PubMedCrossRefGoogle Scholar
  16. 16.
    Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008 Jun; 13(6): 511–4PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Rachna Kasliwal
    • 1
    • 2
  • Lynda V. Wilton
    • 1
    • 2
  • Saad A. W. Shakir
    • 1
    • 2
  1. 1.Drug Safety Research UnitSouthamptonUK
  2. 2.University of PortsmouthPortsmouthUK

Personalised recommendations